Recent advances in intravenous anaesthesia

Area of Science:

• Anesthesiology and pharmacology.
• Drug development and clinical application.

Background:

• Ongoing research into novel hypnotic compounds faces setbacks.
• Propofol has seen various reformulations, with unclear advantages over the original.
• Target-controlled infusion (TCI) is expanding into pediatric anesthesia and sedation.

Purpose of the Study:

• To review recent advancements in anesthetic agents and delivery systems.
• To evaluate the current status of hypnotic drug development and TCI applications.
• To explore the evolving role of ketamine in pain management.

Main Methods:

• Literature review of recent studies on anesthetic agents and technologies.
• Analysis of pharmacokinetic and pharmacodynamic data for propofol preparations.
• Examination of clinical applications and licensing of TCI systems.

Main Results:

• Several new hypnotic compounds have failed in development.
• Pharmacokinetic and pharmacodynamic differences exist among propofol formulations.
• Target-controlled infusion (TCI) is now licensed for remifentanil and used in pediatric anesthesia.
• Ketamine's non-anesthetic analgesic use is increasing, particularly for refractory pain.

Conclusions:

• Despite challenges, advancements in anesthetic delivery and adjunct analgesics continue.
• Further research is needed to clarify the benefits of new propofol formulations.
• Ketamine shows potential as an adjunctive analgesic for specific pain conditions.